| Objective: To objectively evaluate the clinical efficacy and drug safety of Fujiao Tongbian Decoction in the treatment of Constipation predominant irritable bowel syndrome(spleen-kidney yang deficiency type),and to provide clinical basis for the treatment of Constipation predominant irritable bowel syndrome(spleen-kidney yang deficiency type).Methods:This clinical study collected from December 2021 to February 2023 in the Third Affiliated Hospital of Yunnan University of Traditional Chinese Medicine spleen and stomach liver disease outpatient and inpatient patients,will meet the Western medicine diagnosis of constipation-predominant irritable bowel syndrome,TCM syndrome differentiation is spleen and kidney Yang deficiency type of 72 patients,were randomly divided into treatment group and control group,36 cases in each group,the treatment group was given Fujiao Tongbian Decoction,the control group was given Jichuan Decoction,the patients took medicine for 4 weeks,after 6 weeks of withdrawal,the patients were followed up to objectively evaluate the improvement of the efficacy observation indexes and drug safety before and after taking medicine in the two groups.Results:1.TCM syndrome score :(1)In terms of clinical comprehensive efficacy : the effective rate of the treatment group was 88.24 %,and the effective rate of the control group was 73.53 %.The effective rate of the treatment group was higher than that of the control group(P < 0.05).(2)In the total score of TCM syndromes : the total scores of the two groups after treatment were significantly lower than those before treatment(P< 0.05),and the total score of the treatment group decreased more than that of the control group(P< 0.05).(3)In terms of single syndrome score of traditional Chinese medicine : after 2weeks of medication,the symptoms of dry stool,difficult defecation,abdominal pain,clear and long urine,cold limbs and pale complexion in the treatment group were significantly improved compared with those before treatment(P<0.05).In the control group,the symptoms of dry stool,difficult defecation and pale complexion were relieved compared with those before treatment(P<0.05),but there was no significant improvement in abdominal pain,clear and long urine and cold limbs(P> 0.05).After 4 weeks of treatment,the syndrome scores of the two groups were significantly improved before and after treatment(P< 0.05),and the treatment group was superior to the control group in relieving defecation difficulty,abdominal pain,clear urine,cold limbs and pale complexion(P<0.05),but there was no significant difference between the two groups in improving dry stool(P> 0.05).2.Bristol fecal character score:the fecal character scores of the two groups before and after treatment were significantly decreased(P<0.05),However,there was no significant difference in fecal character scores between the two groups after treatment(P >0.05).3.Irritable bowel syndrome quality of life scale score:the quality of life score of the two groups after treatment was significantly higher than that before treatment(P<0.05),and the treatment group was better than the control group(P< 0.05).4.Psychological state score:After treatment,the Hamilton anxiety scale score and Hamilton depression scale score of the two groups showed a downward trend(P<0.05),and the improvement of the treatment group was significantly better than that of the control group(P<0.05).5.Long-term efficacy:After 6 weeks of withdrawal,the effective rate of the treatment group was 83.33 %,and the effective rate of the control group was 52.00%. |
